Adbry Injection, Solution
Product Images NDC 50222-346

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Adbry (NDC 50222-346). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Leo Pharma Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure A (Tralokinumab 01)

Instructional diagram showing labeled parts of the Adbry (tralokinumab-ldrm) prefilled syringe before use including plunger head, plunger rod, finger flange, viewing window, label with expiration date, needle, needle guard clips, and needle cover. The after use image shows the used syringe with the needle guard activated. Instructions note that two injections with separate syringes are required for a full dose.*

FDA Label Image

Figure B (Tralokinumab 02)

Illustration showing the components related to Adbry (tralokinumab-ldrm) injection, solution administration. It includes two Adbry prefilled syringes, an alcohol swab, cotton balls or gauze, and a sharps container for disposal.*

FDA Label Image

Figure C (Tralokinumab 03)

An illustration showing a hand holding a rectangular box, likely representing packaging for a pharmaceutical product. The box has a triangular arrow on the surface and some text on the side, suggestive of typical product packaging instructions or labeling details.*

FDA Label Image

Figure D (Tralokinumab 04)

An instructional illustration depicting a stopwatch showing a 30-minute waiting time. The text below the stopwatch reads 'Waiting time.' This likely indicates a required wait period in a procedure or process.*

FDA Label Image

Figure E (Tralokinumab 05)

An instructional illustration showing a hand holding a syringe being removed from a tray inside a box. The image depicts the process of taking a prefilled syringe from its packaging, likely for a subcutaneous injection.*

FDA Label Image

Figure F (Tralokinumab 06)

An instructional illustration showing a hand holding a prefilled injection syringe with a labeled viewing window, and a close-up of the syringe's needle end. The drawing depicts the correct handling technique for a subcutaneous injection device.*

FDA Label Image

Figure G (Tralokinumab 07)

An anatomical illustration showing recommended injection sites for Adbry (tralokinumab-ldrm) subcutaneous injection. Shaded areas indicate that self-injection or caregiver injection can be done on the abdomen and upper thighs, while injection by caregiver only is marked for the outer upper arms.*

FDA Label Image

Figure H (Tralokinumab 08)

An instructional illustration showing a hand holding a wipe or cloth, cleaning a surface that appears to be a skin area on an arm or leg, likely demonstrating site preparation before a subcutaneous injection.*

FDA Label Image

Figure I (Tralokinumab 09)

An instructional illustration showing a hand holding a syringe with a needle cap being removed. An arrow points to the left, indicating the direction to pull off the needle cap from the syringe before use.*

FDA Label Image

Figure J (Tralokinumab 10)

An instructional illustration showing a hand holding a syringe at a 45-degree angle, positioned above an arm for subcutaneous injection. The image depicts the angle for administering an injection, relevant for products like Adbry injection solution.*

FDA Label Image

Figure K (Tralokinumab 11)

An instructional illustration showing a hand injecting a subcutaneous injection into the abdomen. The image highlights proper placement and technique for administering an injection using a syringe or injector pen, indicated by an arrow pointing to the injection site.*

FDA Label Image

Figure L (Tralokinumab 12)

An instructional illustration depicting a hand administering a subcutaneous injection with a syringe into a forearm, showing the proper injection technique for self-administration.*

FDA Label Image

Figure M (Tralokinumab 13)

An instructional illustration showing a circular arrow symbol with the word "repeat" inside, indicating a repeat action or step in a sequence. The image is simple, using black line art on a light background.*

FDA Label Image

Figure N (Tralokinumab 14)

An instructional illustration showing a hand holding a syringe and placing it into a sharps disposal container, with another syringe already inside the container. The illustration emphasizes safe disposal of used syringes, likely related to subcutaneous injection administration.*

FDA Label Image

Principal Display Panel (150 mg/mL Syringe Carton)

The carton label for Adbry (tralokinumab-ldrm) Injection, 150 mg/mL per syringe, by LEO Pharma Inc. It contains two 1 mL single-dose prefilled syringes (300 mg total) for subcutaneous use only. The packaging includes storage instructions to refrigerate at 36°F to 46°F (2°C to 8°C) and features dosing and handling details alongside the NDC code 50222-346-02.*

FDA Label Image

Principal Display Panel (150 mg/mL Syringe Carton)

The image shows the packaging label for Adbry (tralokinumab-ldrm) Injection, 150 mg/mL per syringe. It is a subcutaneous injection supplied in a multipack containing four 1-mL single-dose prefilled syringes, totaling 600 mg. The labeler is LEO Pharma Inc., and storage instructions include refrigeration between 2°C to 8°C in the original carton to protect from light. The package design includes a syringe illustration and the Adbry logo with decorative colored shapes.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.